Protocol Ledger

NCT06806033 · Phase II · RECRUITING

Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

Interventional Phase II clinical trial protocol NCT06806033 sponsored by Roche / Genentech in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-03-05 Enrollment: 130 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06806033
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)130 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06806033
Protocol FieldVerified Registry Value
NCT IdentifierNCT06806033
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment130 participants (ESTIMATED)
Registered Start Date2025-03-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06806033
Hospital Research SiteLocationSite Profile
Providence Medical FoundationFullerton, CAOpen Hospital Dossier ->
Valkyrie Clinical TrialsLos Angeles, CAOpen Hospital Dossier ->
UCLA Health and Jonsson Comprehensive Cancer CenterLos Angeles, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI